Phase 2 Study of Apixaban Reversal by Ciraparantag as Measured by WBCT
Phase 2 Placebo-Controlled, Single-Site, Single-Blind Study of Apixaban Reversal by Ciraparantag as Measured by WBCT
Sponsor: Perosphere Pharmaceuticals Inc, a wholly owned subsidiary of AMAG Pharmaceuticals, Inc.
A PHASE2 clinical study on Healthy, this trial is completed. The trial is conducted by Perosphere Pharmaceuticals Inc, a wholly owned subsidiary of AMAG Pharmaceuticals, Inc. and has accumulated 11 data snapshots since 2017. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
11 versions recorded-
Oct 2025 — Present [monthly]
Completed PHASE2
-
Sep 2024 — Oct 2025 [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Apr 2022 — Jul 2024 [monthly]
Completed PHASE2
-
Jan 2021 — Apr 2022 [monthly]
Completed PHASE2
▶ Show 6 earlier versions
-
Oct 2020 — Jan 2021 [monthly]
Completed PHASE2
Status: Recruiting → Completed
-
Jun 2020 — Oct 2020 [monthly]
Recruiting PHASE2
-
Dec 2018 — Jun 2020 [monthly]
Recruiting PHASE2
-
Sep 2018 — Dec 2018 [monthly]
Recruiting PHASE2
-
Jun 2018 — Sep 2018 [monthly]
Recruiting PHASE2
-
Oct 2017 — Jun 2018 [monthly]
Recruiting PHASE2
First recorded
Aug 2017
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Perosphere Pharmaceuticals Inc, a wholly owned subsidiary of AMAG Pharmaceuticals, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .